• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

SterRx Recalls 240 Lots of 12 Products

Article

Equipment and process issues could lead to a lack of sterility.

SterRx is recalling about 240 lots of 12 different products. The recall is being made because of due equipment and process issues that could lead to a lack of sterility. To date, SterRx has not received reports of adverse events associated.

These lots were distributed between December 2020 and October 2021.

The products impacted include:

  • 1mg/mL Midazolam in 0.9% Sodium Chloride
  • Fentanyl in 0.9% Sodium Chloride
  • 1mg/mL Morphine Sulfate in 0.9% Sodium Chloride
  • 1mg/mL Morphine Sulfate in 5% Dextrose
  • 125mg Diltiazem HCL in 0.7% Sodium Chloride
  • 125mg Diltiazem HCL in 5% Dextrose
  • Norepinephrine in 0.9% Sodium Chloride
  • Norepinephrine in 5% Dextrose
  • Epinephrine in 0.9% Sodium Chloride
  • Phenylephrine in 0.9% Sodium Chloride
  • 150mEq Sodium Bicarbonate in 5% Dextrose
  • 200mg Succinylcholine Chloride in 0.9% Sodium Chloride

Those with questions should call (518) 324-7983 or email Recall@sterrx.com.

Related Content
© 2024 MJH Life Sciences

All rights reserved.